Fidelity Advisor Biotechnology Fund (FBTCX)
Fund Summary
The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments. The fund is non-diversified.
Fidelity Advisor Biotechnology Fund
Fund Overview
Category | Health |
Fund Family | Fidelity Investments |
Net Assets | 1.37B |
YTD Return | -4.51% |
Yield | 2.88% |
Morningstar Rating | |
Inception Date | Dec 27, 2000 |
Fund Operations
Last Dividend | 0.60 |
Last Cap Gain | 37.00 |
Holdings Turnover | 73.00% |
Average for Category | -- |
Fees & Expenses
Expense | FBTCX | Category Average |
---|---|---|
Annual Report Expense Ratio (net) | 1.71% | 1.03% |
Prospectus Net Expense Ratio | 1.71% | -- |
Prospectus Gross Expense Ratio | 1.71% | -- |
Max 12b1 Fee | -- | -- |
Max Front End Sales Load | -- | 5.37% |
Max Deferred Sales Load | -- | 1.19% |
3 Yr Expense Projection | 0 | -- |
5 Yr Expense Projection | 0 | -- |
10 Yr Expense Projection | 0 | -- |
Management Information
Morningstar Style Box
